|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM228414822 |
| 003 |
DE-627 |
| 005 |
20250215131251.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2013 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2013.04.017
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0761.xml
|
| 035 |
|
|
|a (DE-627)NLM228414822
|
| 035 |
|
|
|a (NLM)23773922
|
| 035 |
|
|
|a (PII)S1521-6616(13)00121-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Llanos, Carolina
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Tolerogenic dendritic cells as a therapy for treating lupus
|
| 264 |
|
1 |
|c 2013
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.09.2013
|
| 500 |
|
|
|a Date Revised 15.07.2013
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2013 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that is characterized by the over production of auto-antibodies against nuclear components. Thus, SLE patients have increased morbidity and, mortality compared to healthy individuals. Available therapies are not curative and are associated with unwanted adverse effects. During the last few years, important advances in immunology research have provided rheumatologists with new tools for designing novel therapies for treating autoimmunity. However, the complex nature of SLE has played a conflicting role, hindering breakthroughs in therapeutic development. Nonetheless, new advances about SLE pathogenesis could open a fruitful line of research. Dendritic cells (DCs) have been established as essential players in the mechanisms underlying SLE, making them attractive therapeutic targets for fine-tuning the immune system. In this review, we discuss the recent advances made in revealing the mechanisms of SLE pathogenesis, with a focus on the use of DCs as a target for therapy development
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Autoimmune diseases
|
| 650 |
|
4 |
|a Dendritic cells
|
| 650 |
|
4 |
|a Immune tolerance
|
| 650 |
|
4 |
|a Immunotherapy
|
| 650 |
|
4 |
|a Lupus
|
| 700 |
1 |
|
|a Mackern-Oberti, Juan Pablo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Vega, Fabián
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jacobelli, Sergio H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kalergis, Alexis M
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 148(2013), 2 vom: 17. Aug., Seite 237-45
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:148
|g year:2013
|g number:2
|g day:17
|g month:08
|g pages:237-45
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2013.04.017
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 148
|j 2013
|e 2
|b 17
|c 08
|h 237-45
|